Interventional × Cholangiocarcinoma × Endocrine × Clear all
NCT02834013 2026-03-18

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
818 enrolled
NCT02568267 2026-03-06

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
NCT05286814 2026-02-24

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
70 enrolled
NCT04459273 2026-02-05

FAPI PET RDRC

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
26 enrolled
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 5 FDA
NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

Phase 1 Recruiting
30 enrolled
NCT06638931 2025-05-28

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Active not recruiting
28 enrolled
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled